Barclays PLC Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Barclays PLC boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 79.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 107,542 shares of the company's stock after acquiring an additional 47,528 shares during the quarter. Barclays PLC owned 0.27% of Keros Therapeutics worth $1,703,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. AlphaQuest LLC increased its holdings in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Keros Therapeutics in the fourth quarter worth about $90,000. Exchange Traded Concepts LLC acquired a new position in shares of Keros Therapeutics in the fourth quarter valued at about $99,000. China Universal Asset Management Co. Ltd. lifted its position in Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after purchasing an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB boosted its position in Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.06 during trading hours on Thursday, hitting $13.77. The stock had a trading volume of 82,065 shares, compared to its average volume of 1,320,667. The stock has a market capitalization of $559.21 million, a price-to-earnings ratio of -2.64 and a beta of 1.32. The stock's fifty day moving average is $12.10 and its two-hundred day moving average is $25.34. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same quarter in the prior year, the firm earned ($1.21) EPS. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a report on Thursday, January 16th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Cantor Fitzgerald lowered Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Finally, Piper Sandler lowered their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.67.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.